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Enhanced leukocyte recruitment is an inﬂammatory process that occurs during early phases of the
vascular dysfunction that characterises atherosclerosis. We evaluated the impact of anti-TNF-α (adali-
mumab, inﬂiximab and etanercept) and anti-IL-12/23 (ustekinumab) on interactions between human
leukocytes and endothelial cells in a ﬂow chamber that reproduced in vivo conditions. Clinical con-
centrations of anti-TNF-α were evaluated on the leukocyte recruitment induced by a variety of en-
dothelial (TNF-α, interleukin-1β, lymphotoxin-α and angiotensin-II) and leukocyte (PAF, IL-12 and IL-23)
stimuli related to inﬂammation and atherosclerosis. Treatment with anti-TNF-α, even before or after
establishing the inﬂammatory situation induced by TNF-α, diminished leukocyte–endothelial cell in-
teractions induced by this stimuli. Our results also implicated adhesion molecules (ICAM-1, VCAM-1 and
E-selectin) in the actions of anti-TNF-α in terms of leukocyte adhesion to endothelium. However, anti-
TNF-α drugs did not inﬂuence the actions of interleukin-1β, but prevented those of lymphotoxin-α and
angiotensin-II. However, once established, inﬂammatory response elicited by the latter three stimuli
could not be reversed. Pre-treatment with anti-TNF-α, also prevented leukocyte actions induced by IL-23
on PBMC rolling ﬂux and rolling velocity and by IL-12 on PMN adhesion. Ustekinumab exhibited a more
discreet proﬁle, having no effect on leukocyte recruitment induced by any of the endothelial stimuli,
while blocking the effects of IL-23 on leukocyte activation and those of IL-12 on PMN adhesion and PAF
on PBMC rolling velocity. These ﬁndings endorse the idea that biological anti-inﬂammatory drugs, in
particular anti-TNF-α, have the capacity to inﬂuence cardiovascular risk accompanying psoriasis and
rheumatoid arthritis by ameliorating vascular inﬂammation.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The increased risk of early cardiovascular disease (CVD) in pa-
tients with autoimmune diseases such as psoriasis (PS) and
rheumatoid arthritis (RA) has been attributed to an acceleration of
atherosclerosis produced by the systemic inﬂammation thatr B.V. This is an open access article
acología, Facultad de Medici-
5-17, 46010 Valencia, Spain.
o),
s (V. Collado-Diaz),
s-Garcia),
ez@uv.es (A. Alvarez).characterizes said diseases (Roubille et al., 2015; Westlake et al.,
2011; Spah, 2008; Alexandroff et al., 2009). Manifestations of
vascular inﬂammation involving interaction between adhesion
molecules on leukocytes and on the endothelium are one of the
early hallmarks of plaque formation and lead to the accumulation
of leukocytes in the vessel wall (Ley et al., 2007). Although all
immunosuppressive therapies have the potential to interfere with
such interactions, there is mounting evidence that anti-in-
ﬂammatory biologic drugs used to treat PS and RA can ameliorate
vascular systemic inﬂammation and reduce the risk of CVD
(Westlake et al., 2011; Maki-Petaja et al., 2012; Ahlehoff et al.,
2013; Tam et al., 2014; Ridker and Luscher, 2014; Nguyen and Wu,
2014; Roubille et al., 2015).
Evidence regarding anti-TNF-α therapies is particularly com-
pelling, probably due to the widespread involvement of saidunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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(Elliott et al., 1994; Westlake et al., 2011; Roubille et al., 2015).
However, theories concerning the mechanisms implicated are ra-
ther spurious, as these drugs have been related both, with heart
failure and a reduction in inﬂammation and plaque formation.
There is also a case for analyzing anti-IL-12/23 agents given the
potential implication of both these cytokines in plaque formation
and their frequent use in the treatment of PS as alternatives to
anti-TNF-α; however, some reports have related them with an
increase in adverse cardiovascular events, which calls into ques-
tion their validity (Ahlehoff et al., 2013; Alexandroff et al., 2009).
The aim of the present study was to characterize the effects of
the most widely used anti-TNF-α-adalimumab (ADA, fully human),
inﬂiximab (INF, chimeric origin with human constant and murine
variable regions) and etanercept [ETA, human p75 region of tumor
necrosis factor-α (TNF-α) receptor linked to the fragment crys-
tallisable (Fc) region of human IgG1]-on leukocyte–endothelial cell
interactions and endothelial adhesion molecules induced by var-
ious stimuli implicated in PS and RA, and to compare the effects
with those of the anti-p40 subunit of IL-12/23 ustekinumab (UST)
(Nestorov, 2005; Tracey et al., 2008; Koutruba et al., 2010; Price
et al., 2007; Singh et al., 2011).2. Materials and methods
2.1. Human umbilical vein endothelial cells (HUVEC) cell culture
HUVEC were harvested from freshly obtained umbilical cords
by collagenase treatment, as previously described (De Pablo et al.,
2010). In short, umbilical cord veins were rinsed of blood products
with warm phosphate-buffered saline (PBS), after which the vein
was ﬁlled with collagenase (1 mg/ml) for 17 min at 37 °C. The
cords were then gently massaged to ensure detachment of en-
dothelial cells from the vessel wall. The digest was collected,
centrifuged and pelleted. The pellet was resuspended in en-
dothelial cell growth medium (EGM-2) inside T25 culture ﬂasks in
which cells were cultured until conﬂuence. After reaching con-
ﬂuence, primary cultures were detached with trypsin and trans-
ferred to 6-well plate culture dishes. Passage 1 of these primary
cultures was subsequently employed. For adhesion studies, HUVEC
were cultured on ﬁbronectin (5 μg/ml)-coated 25-mm plastic
coverslips until conﬂuent (∼48 h).
2.2. Leukocyte isolation
Polymorphonuclear (PMN) or peripheral blood mononuclear
(PBMC) cells were isolated from whole blood drawn from healthy
volunteers and anticoagulated with sodium citrate (De Pablo et al.,
2010). Samples were incubated with dextran (3%) for 45 min.
PBMC and PMN in the supernatant were separated by gradient
density centrifugation (250 g, 25 min) with Ficoll-Paque™ Plus.
After red blood cell lysis, leukocytes were washed (HBSS without
Ca2þ or Mg2þ) and resuspended in complete RPMI media. The
medical ethical committee of the Hospital Clínico Universitario de
Valencia approved the study and all participating patients pro-
vided written informed consent.
2.3. Adhesion assay under ﬂow conditions
The parallel plate ﬂow chamber in vitro model has been de-
scribed in detail previously (De Pablo et al., 2012; Cai et al., 2006).
For adhesion assays, coverslips containing conﬂuent HUVEC
monolayers were placed in a circular recess in the bottom plate of
the ﬂow chamber (maintained at 37 °C), where a portion (5
mm × 25 mm) of the monolayer was exposed to the ﬂow. Theentire chamber was mounted on an inverted microscope (Nikon
Eclipse TE 2000-S) connected to a video camera (Sony Exware
HAD). Experiments were conducted using a 40 objective lens.
PMN or PBMC were resuspended in ﬂow buffer (DPBSþ containing
20 mM HEPES and 0.1% HSA) at 1106 or 0.5106 cells/ml re-
spectively and were drawn across the HUVEC monolayer at a
controlled ﬂow rate of 0.36 ml/min (estimated shear stress of
0.7 dyne/cm2). A circular glass window in the top plate of the
chamber allowed real-time microscopic examination of the
monolayer exposed to the ﬂow. Images in a single ﬁeld of view
were recorded over a 5-min period during which leukocyte
parameters were determined. Leukocyte rolling was calculated by
counting the number of leukocytes passing a reference point in the
monolayer during a period of 1 min. The velocities of 20 con-
secutive leukocytes in the ﬁeld of focus were determined by
measuring the time required to travel a distance of 100 μm.
Leukocyte adhesion was determined by counting the number
of leukocytes that maintained stable contact with the monolayer
for 30 s.
Two series of experiments were carried out in order to perform
a comprehensive evaluation of the mechanisms and cell popula-
tions implicated and the pharmacological features of the drugs
under assay. Initially, we focused on the role of the endothelium
when activated by stimuli at doses that have been correlated with
the onset of the inﬂammatory process in atherosclerosis (Libby,
2012; Alvarez et al., 2004): TNF-α (25 ng/ml, 4 h), IL-1β (inter-
leukin-1β, 80 IU/ml, 4 h), LT-α (lymphotoxin-α, 3 ng/ml, 4 h) and
Ang-II (angiotensin-II, 10 nM, 4 h) (Nakada et al., 1998; Yamagata
et al., 2012; Suna et al., 2008; Mateo et al., 2006). When necessary,
HUVEC were pre-treated (0.5 h before) or post-treated (0.5, 4 or
24 h after activation of the endothelium) with clinically relevant
concentrations of ADA (3–11 mg/ml), INF (200 mg/ml), ETA (5 mg/
ml) or UST (3–15 mg/ml) (Rigby, 2007; Nestorov, 2005; Furst et al.,
2006; Gottlieb et al., 2007).
The second group of experiments was designed to explore the
role of leukocytes. Hence, PMN or PBMC were stimulated with the
general leukocyte activator Platelet-activating factor (PAF; 1-O-
alkyl-2-acetyl-sn-glycero-3-phosphocholine, 10 mM, 1 h) (Mon-
trucchio et al., 2000) or with stimuli speciﬁcally known to provoke
leukocyte activation in psoriatic arthritis (Koutruba et al., 2010;
Suzuki et al., 2014; Lowes et al., 2013): IL-12 (interleukin-12, 5 ng/
ml, 1 h) and IL-23 (interleukin-23, 50 ng/ml, 1 h) (Allavena et al.,
1994). When necessary, PMN or PBMC were pre-treated (0.5 h
before activation of leukocytes) with clinically relevant con-
centrations of ADA and UST. Post-activation treatment could not
be performed because of limits in the leukocytes' integrity.
2.4. Expression of adhesion molecules in HUVEC
Endothelial adhesion molecules [ICAM (intercellular adhesion
molecule)-1, VCAM (vascular adhesion molecule)-1 and E-selectin]
were analyzed as described previously (Alvarez et al., 2004; Ibiza
et al., 2009). HUVEC were grown to conﬂuence in 6-well plates
and thereafter stimulated with TNF-α (25 ng/ml) for 4 h at 37 °C.
Some cells were treated with ADA (0.01–11 mg/ml) 0.5 h before or
24 h after activation of the endothelium. Cells were detached with
trypsin, placed in suspension, incubated with the corresponding
antibody (20 min, on ice, in darkness), ﬁxed (in formaline 10%) and
analyzed for protein expression according to forward- and side-
scatter characteristics in a FACS Calibur cytometer (BD, Franklin
Lakes, NJ, USA). In each case, 10,000 cells were analyzed and the
mean of the speciﬁc ﬂuorescence intensity was employed as a
marker of the expression of the respective epitope. All samples
were compensated using the appropriate isotype-matched nega-
tive control.
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Dulbecco's PBS, with (DPBSþ) or without (DPBS) Ca2þ and
Mg2þ , EGM-2 culture media, HBSS and fetal bovine serum were
acquired from LONZA (Verviers, Belgium). Recombinant TNF-α,
human serum albumine (HSA, Albuminate 25%), RPMI1640 sup-
plemented with 20 mM HEPES, ﬁbronectin, formaline, dextran, IL-
1β, IL-12, PAF and Ang-II were supplied by Sigma Chemical Co (St.
Louis, MO, USA). LT-α and IL-23 were acquired from Prospecbio
(supplied by Deltaclon, Madrid, Spain). Ficoll-Paque TM Plus was
supplied by GE Healthcare Life Sciences (Amersham, UK). Plastic
coverslips with a diameter of 25 mm were obtained from Nunc,
supplied by Thermo Fisher Scientiﬁc (Walthman, MA, USA). PBS,Fig. 1. Effects of pre-treatment with adalimumab or ustekinumab on PMN- or PBMC
with adalimumab (ADA, 3–11 mg/ml) or ustekinumab (UST, 15 mg/ml) before stimulatio
morphonuclear (PMN) cells rolling velocity (a), rolling ﬂux (b) and adhesion (c) and p
adhesion (f) were quantiﬁed after assembling the ﬂow chamber. Results are mean7S.
*Po0.05 or **Po0.01 vs. corresponding value in TNF-α-treated group (ANOVA followedcollagenase, and trypsin were acquired from Gibco Invitrogen, Life
Technologies (Carlsbad, CA, USA). Fluorescein isothyocianate (FITC)
and phycoerithrin (PE) conjugated control antibodies and anti-
bodies against E-selectin, ICAM-1 or VCAM-1 were purchased
from BD Bioscience (Franklin Lakes, NJ, USA). Adalimumab (Hu-
miras), inﬂiximab (Remicades), etanercept (Enbrels) and uste-
kinumab (Stelaras) were used in the form of their clinically
available preparations.
2.6. Data analysis and statistics
Data are mean7S.E.M of 3–6 experiments. Statistical sig-
niﬁcance was considered to be o0.05 by one-way ANOVA analysis-endothelial cell interactions induced by TNF-α. HUVEC were pre-treated (0.5 h)
n (4 h) with tumor necrosis factor-α (TNF-α, 25 ng/ml) or medium (control). Poly-
eripheral blood mononuclear cells (PBMC) rolling velocity (d), rolling ﬂux (e) and
E.M., nZ4. þPo0.05 or þ þPo0.01 vs. corresponding value in control group and
by Newman–Keuls test).
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multiple variances.3. Results
3.1. Effects on cell interactions induced by endothelial stimuli
As expected, only a small number of PMN or PBMC cells ad-
hered to unstimulated HUVEC (Figs. 1, 2, 4, 5 and 6), thus re-
producing the conditions of a normal non-inﬂamed vessel (Sup-
plementary material S1). In order to mimic the typical scenario ofFig. 2. Capacity of adalimumab and ustekinumab to reverse PMN- or PBMC-endoth
necrosis factor-α (TNF-α, 25 ng/ml) or medium (control) before incubation with adalimu
Polymorphonuclear (PMN) cells rolling velocity (a), rolling ﬂux (b) and adhesion (c) and
adhesion (f) were quantiﬁed after assembling the ﬂow chamber. Results are mean7S.
*Po0.05 or **Po0.01 vs. corresponding value in TNF-α-treated group (ANOVA followedthe development of the atherosclerotic plaque, HUVEC were sti-
mulated with TNF-α, IL-1β, LT-α or Ang-II.
TNF-α (Supplementary material S2) induced a signiﬁcant de-
crease in the rolling velocity and an increase in the rolling ﬂux and
adhesion of both PMN and PBMC (Figs. 1 and 2). ADA prevented
leukocyte (PMN and PBMC)-endothelial cell interactions induced
by TNF-α in a dose-dependent manner (Supplementary movies S3,
S4 and S5). The actions of the anti-TNF-α on adhesion were more
pronounced than those on rolling, and this pattern was particu-
larly obvious in PMN, in which the lowest concentration employed
(3 mg/ml) signiﬁcantly reduced adhesion while having no effect on
rolling velocity or ﬂux (Fig. 1). Of note, 24 h treatment withelial cell interactions induced by TNF-α. HUVEC were treated (4 h) with tumor
mab (ADA, 0.1–11 mg/ml) or ustekinumab (UST, 15 mg/ml) for a further 24 h period.
peripheral blood mononuclear cells (PBMC) rolling velocity (d), rolling ﬂux (e) and
E.M., nZ4. þPo0.05 or þ þPo0.01 vs. corresponding value in control group and
by Newman–Keuls test).
Table 1
Capacity of adalimumab, inﬂiximab and etanercept to reverse PMN- or PBMC-endothelial cell interactions induced by TNF-α.
Vehicle TNF-α TNF-αþADA TNF-αþINF TNF-αþETA
PMN Rolling velocity (lm/seg) 898,81726,7 546,33724,8aa 557,87761,9aa 563,25770,6aa 651,33775,7aa
Rolling ﬂux (cells/min) 65,0475,7 218,75728,3aa 209,25725,3aa 176,57714,5aa 166,08723,1aa
Adhesion (cells/mm2) 2,6270,3 290,32735,1aa 8,4672,2bb 11,2577,6bb 10,7376,1bb
PBMC Rolling velocity (lm/seg) 875,72722,8 531,38725,1aa 609,33749,8aa 667,10728,9aa 659,23728,9aa
Rolling ﬂux (cells/min) 65,3175,9 142,3377,5aa 120,579,3aa 106,6778,8aa 108,67714,5aa
Adhesion (cells/mm2) 3,2270,4 87,72711,1aa 3,9371,2bb 1,9570,7bb 4,9470,8bb
HUVEC were treated (4 h) with tumor necrosis factor-α (TNF-α, 25 ng/ml) or medium (control) before incubation with adalimumab (ADA, 11 mg/ml), inﬂiximab (INF, 200 mg/
ml) or etanercept (ETA, 5 mg/ml) for a further 24 h period. Polymorphonuclear (PMN) cells rolling velocity, rolling ﬂux and adhesion and peripheral blood mononuclear cells
(PBMC) rolling velocity, rolling ﬂux and adhesion were quantiﬁed after assembling the ﬂow chamber. Results are mean7S.E.M., nZ3.
aa Po0.01 vs. corresponding value in control group.
bb Po0.01 vs. corresponding value in TNF-α-treated group (ANOVA followed by Newman–Keuls test).
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the adhesion of leukocytes following endothelium activation (4 h)
by TNF-α without affecting earlier steps of the vascular in-
ﬂammatory process, such as leukocyte rolling velocity and ﬂux
(Fig. 2). Shorter periods of incubation with ADA (i.e., 0.5 h or 4 h)
had no effect on the changes in leukocyte parameters induced by
4 h incubation with TNF-α (data not shown). 24 h incubation with
INF and ETA produced a similar proﬁle to ADA in terms of rever-
sing leukocyte recruitment induced by 4 h TNF-α; i.e., leukocyte
adhesion was reversed without disturbing rolling velocity or ﬂux
(Table 1). UST, whether used pre- or post-TNF-α, had no effect on
any of the leukocyte–endothelial cell interactions induced by this
inﬂammatory cytokine.
Supplementary material related to this article can be found
online at http://dx.doi.org/10.1016/j.ejphar.2015.08.054.
TNF-α (25 ng/ml) increased the expression of VCAM-1, ICAM-1
and E-selectin (Fig. 3, Supplementary Fig. S1) in HUVEC. ADA both
prevented and reversed the induction of these adhesion mole-
cules, even at very low concentrations (0.3 mg/ml).
IL-1β and LT-α also induced a signiﬁcant decrease in the rolling
velocity and an increase in the rolling ﬂux and adhesion of both
PMN and PBMC (Figs. 4 and 5). In the case of Ang-II, there was a
similar and signiﬁcant decrease of rolling velocity and an increase
in rolling ﬂux both in PMN and PBMC, while only PMN adhesion
was increased by this peptide (Figs. 4 and 5). TNF-α evidently had
no bearing on the effects of IL-1β on leukocyte recruitment, since
pre-treatment with ADA did not alter the response of PMN or
PBMC to this stimulus. On the contrary, some TNF-α-activated
receptors seemed to be implicated in the inﬂammatory actions of
LT-α, as all parameters of PMN- and PBMC-endothelial interactions
elicited by this cytokine were signiﬁcantly prevented by the
highest dose of ADA employed (11 mg/ml). Once again, ADA had a
greater impact on adhesion (a complete return to control levels)
than on rolling velocity and ﬂux, which were only partially pre-
vented (Fig. 4). ADA's effect on the actions of Ang-II on PMN were
similar to those on LT-α, while Ang-II has no bearing on PBMC
(Fig. 4). Finally, pre-incubation with UST had no effect on leuko-
cyte–endothelial cell interactions induced by IL-1β, LT-α or Ang-II
(Fig. 4).
In a scenario where the endothelium had previously been ac-
tivated by IL-1β, LT-α or Ang-II (4 h), 24 h post-treatment with
either ADA or UST did not reverse the leukocyte–endothelial cell
interactions elicited by all three stimuli (Fig. 5).
3.2. Effects on cell interactions induced by leukocyte stimuli
Leukocytes were stimulated with three mediators that have
been correlated with inﬂammation in atherosclerosis or PS. PAF, a
broad and unspeciﬁc leukocyte activator, induced a signiﬁcant
decrease in rolling velocity and an increase in rolling ﬂux andadhesion of both PMN and PBMC (Fig. 6). ADA had no effect on
these actions, and, while UST also lacked an inﬂuence on any of the
effects of PAF on PMN, it speciﬁcally reduced PBMC rolling ﬂux. IL-
23 induced a reduction in PMN and PBMC rolling velocity and
increased rolling ﬂux. While ADA reversed the effects of IL-23 on
PBMC only, UST blocked these effects on both leukocyte popula-
tions. IL-12 had no effect at physiological doses and affected only
PMN at very high doses (50-fold), reducing their rolling velocity
and increasing their rolling ﬂux and adhesion. Both ADA and UST
reversed the effects of IL-12 on adhesion, but not on rolling velo-
city or rolling ﬂux (Fig. 6).4. Discussion
The exacerbation of leukocyte–endothelial interactions is an
inﬂammatory process associated with the early phases of the
vascular dysfunction that characterises important cardiovascular
diseases (Krieglstein and Granger, 2001). The aim of the present
study was to compare the actions of two of the most potent anti-
inﬂammatory treatments for PS – anti-TNF-α and anti-IL-12/23
agents – on a variety of endothelial (TNF-α, IL-1β, LT-α and Ang-II)
and leukocyte (PAF, IL-12 and IL-23) stimuli implicated in en-
dothelial dysfunction and/or PS pathogenesis (Tracey et al., 2008;
Koutruba et al., 2010; Price et al., 2007; Singh et al., 2011). We
employed a dynamic in vitro model that is widely used to analyze
the multistep recruitment of leukocytes and the vascular anti-in-
ﬂammatory actions of drugs (Victor et al., 2011; Luu et al., 2007). In
this system, human leukocytes (PMN and PBMC) ﬂow over a
monolayer of human endothelial cells in a way that closely re-
sembles processes (rolling and adhesion) that are critical for he-
mostasis and vascular cell integrity and which precede the for-
mation of an atherosclerotic plaque in vivo (Goetz et al., 1999; De
Pablo et al., 2013). Our results demonstrate that clinically relevant
concentrations of the three anti-TNF-α drugs tested, but not of
UST, signiﬁcantly undermine leukocyte recruitment when the
endothelium is activated. However, when leukocytes are activated,
UST reduces some, but not all, of these interactions, while, sur-
prisingly, ADA also exerts a signiﬁcant effect.
Pre-incubation with concentrations of ADA (3–11 μg/ml) that
mimicked those present in patients (Rigby, 2007; Nestorov, 2005;
Furst et al., 2006) prevented all the effects induced by subsequent
administration of TNF-α, one of the most potent stimuli of leu-
kocyte–endothelial interplay (Grifﬁn et al., 2012). On the other
hand, when an inﬂammatory response to TNF-α had been estab-
lished – a scenario that resembles clinical conditions more closely
– subsequent treatment with any of three anti-TNF-α evaluated
(ADA, INF or ETA) also reversed the effects of this mediator on
adhesion, while having no inﬂuence on its effects on rolling ve-
locity and ﬂux, despite the on-going presence of the cytokine.
Fig. 3. Effects of adalimumab on the expression of endothelial adhesion molecules induced by TNF-α. HUVEC were treated with adalimumab (ADA, 0.01–11 mg/ml) 0.5 h
before (a–c) or 24 h after (d-f) stimulation (4 h) with tumor necrosis factor-α (TNF-α, 25 ng/ml) or medium (control). Expression of vascular cell adhesion molecule-1 (VCAM-
1) (a and d), intracellular adhesion molecule-1 (ICAM-1) (b and e) and E-selectin (c and f) was analyzed by ﬂow cytometry. Fluorescein isothyocianate (FITC) or phycoerithrin
(PE)-ﬂuorescence values are expressed as a percentage of the mean ﬂuorescence intensities of control cells (100%). Results are mean7S.E.M., nZ3. þPo0.05 or þ þPo0.01
vs. corresponding values in control group and **Po0.01 vs. corresponding value in TNF-α-treated group (ANOVA followed by Newman–Keuls test).
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receptors were not noticeable after short periods (0.5 h or 4 h) of
anti-TNF-α incubation and reached signiﬁcance only after 24 h,
which is evidence of the multiple inﬂammatory pathways trig-
gered following administration of the cytokine and its reduced
role in subsequent responses. In addition, ADA had no inﬂuence on
the actions of IL-1β, but prevented the actions of LT-α and Ang-II
when pre-administered. However, ADA failed to reverse the in-
ﬂammatory response elicited by the latter two stimuli once it had
been established. The effects described with ADA, which binds to
TNF-α and avoids the interaction of this cytokine with its two
receptors (TNF receptor 1 and TNF receptor 2) (Van et al., 2011),are generally in line with published evidence implicating TNF-α in
the actions of the stimuli we have evaluated in this study. Thus,
whereas IL-1β exerts its action through receptors unrelated to
TNF-α (Dinarello, 2011), LT-α exhibits certain similarity with the
tertiary and quaternary structure of TNF-α (Buhrmann et al., 2013),
which probably explains its susceptibility to TNF-α blockade. In-
deed, its actions are a result of its binding to a variety of receptors,
including TNF receptor 1 and TNF receptor 2 and the more speciﬁc
LT-β receptor (Etemadi et al., 2013). Lastly, Ang-II binds to angio-
tensin-II receptor type I, which activates signal pathways shown to
upregulate TNF-α production (Abadir et al., 2011).
The interaction of leukocytes with endothelial cells is
Fig. 4. Effects of pre-treatment with adalimumab or ustekinumab on PMN- or PBMC-endothelial cell interactions induced by IL-1β, LT-α or Ang-II. HUVEC were pre-
treated (0.5 h) with adalimumab (ADA, 11 mg/ml) or ustekinumab (UST, 15 mg/ml) before stimulation (4 h) with interleukin-1β (IL-1β, 80 IU), lymphotoxin-α (LT-α, 3 ng/ml),
angiotensin II (Ang-II, 10 nM) or medium (control). Polymorphonuclear (PMN) cells rolling velocity (a), rolling ﬂux (b) and adhesion (c) and peripheral blood mononuclear
cells (PBMC) rolling velocity (d), rolling ﬂux (e) and adhesion (f) were quantiﬁed after assembling the ﬂow chamber. Results are mean7S.E.M., nZ3. þPo0.05 or
þ þPo0.01 vs. corresponding value in control group and *Po0.05 or **Po0.01 vs. corresponding value in IL-1β, LT-α or Ang-II-treated group (ANOVA followed by Newman–
Keuls test).
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cell groups (Ley et al., 2007; Muller, 2009). However, until now,
there has been very little evidence of the implication of these
molecules in the protective cardiovascular actions of anti-TNF-α,
and the few existing reports have assessed non-functional soluble
forms of adhesion molecules in plasma (Gonzalez-Gay et al., 2006;
den Broeder et al., 2002; Klimiuk et al., 2004). In addition, most
studies have been performed with INF and ETA, and so very little
data has been obtained regarding newer, “non-chimeric” anti-TNF-
α. Our results clearly endorse a role for adhesion molecules in the
actions of anti-TNF-α, particularly as we have measured theexpression of functional molecules – not just soluble ones – in the
very same endothelial cell monolayer in which the ﬂow chamber
studies were performed. We can conﬁrm previous evidence that
TNF-α induces the expression of ICAM-1, VCAM-1 and E-selectin
(Zhang et al., 2002), and we demonstrate that this enhancement is
prevented and reversed by concentrations of ADA well below
clinical levels. The fact that ICAM-1, VCAM-1 and E-selectin are
responsible for leukocyte adhesion would explain why ADA re-
verses this speciﬁc parameter and not rolling velocity and ﬂux,
which would seem to implicate other molecules (Muller, 2009; Ley
et al., 2007). This proﬁle of the actions of anti-TNF-α is of special
Fig. 5. Capacity of adalimumab and ustekinumab to reverse PMN- or PBMC-endothelial cell interactions induced by IL-1β, LT-α or Ang-II. HUVEC were treated (4 h)
with interleukin-1β (IL-1β, 80 IU), lymphotoxin-α (LT-α, 3 ng/ml), angiotensin II (Ang-II, 10 nM) or medium (control) before incubation with adalimumab (ADA, 11 mg/ml) or
ustekinumab (UST, 15 mg/ml) for a further 24 h period. Polymorphonuclear (PMN) cells rolling velocity (a), rolling ﬂux (b) and adhesion (c) and peripheral blood mononuclear
cells (PBMC) rolling velocity (d), rolling ﬂux (e) and adhesion (f) were quantiﬁed after assembling the ﬂow chamber. Results are mean7S.E.M., nZ4. þPo0.05 or
þ þPo0.01 vs. corresponding value in control group (ANOVA followed by Newman–Keuls test).
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cells with the endothelium and occurs immediately prior to dya-
pedesis/emigration, the “point of no return” in leukocyte in-
ﬂammatory vascular enrollment (Muller, 2009). Of note, this re-
sponse is in keeping with that of drugs such as natalizumab (anti-
α4 integrin antibody) and roquinimix, which also abolish leuko-
cyte adhesion, but not rolling, under TNF-α-stimulating conditions
(Coisne et al., 2009; Zhang et al., 2000).
UST had no effect on the leukocyte recruitment induced by any
of the four stimuli used to activate the endothelium, as was ex-
pected given the limited evidence of the implication of IL-12 and
IL-23, whose p40 subunit is blocked by UST, in the inﬂammatory
responses of HUVEC. However, UST prevented the effects of IL-23on leukocyte activation and the PMN adhesion induced by IL-12.
UST would seem to block both cytokines, thus avoiding their
binding to the IL-12 β1 receptor chain of both IL-12 (IL-12 β1/β2)
and IL-23 (IL-12β1/IL-23) receptor complexes (Suzuki et al., 2014;
Lowes et al., 2013; Benson et al., 2011). IL-12 exerted a differential
proﬁle on both leukocyte subpopulations in terms of leukocyte–
endothelial cells interactions by inducing them only on PMN but
not on PBMC. Similar results were observed by Allavena et al.
(1994) when evaluated the chemotactic response of PMN and
PBMC to the cytokine IL-12. However, the effects of IL-12 on PMN
rolling were not blocked by UST, but this result needs to be in-
terpreted with caution given the clinical concentration of IL-12 on
psoriatic patients (36.6717.93 pg/ml, Arican et al., 2005) is much
Fig. 6. Effects of pre-treatment with adalimumab or ustekinumab on PMN- or PBMC-endothelial cell interactions induced by PAF, IL-23 or IL-12. PMN and PBMC were
pre-treated with adalimumab (ADA, 11 mg/ml) or ustekinumab (UST, 15 mg/ml) for 0.5 h before stimulation (1 h) with platelet-activating factor (PAF, 10 mM), interleukin-23
(IL-23, 50 pg/ml), interleukin-12 (IL-12, 5 ng/ml) or medium (control). Polymorphonuclear (PMN) cells rolling velocity (a), rolling ﬂux (b) and adhesion (c) and peripheral
blood mononuclear cells (PBMC) rolling velocity (d), rolling ﬂux (e) and adhesion (f) were quantiﬁed after assembling the chamber. Results are mean7S.E.M., nZ4.
þPo0.05 or þ þPo0.01 vs. corresponding value in control and *Po0.05 or **Po0.01 vs. corresponding value in PAF or IL-23 or IL-12-treated group (ANOVA followed by
Newman–Keuls test).
C. Ríos-Navarro et al. / European Journal of Pharmacology 765 (2015) 355–365 363lower than the concentration necessary to induce in vitro leuko-
cyte–endothelial cell interactions (5000 pg/ml; Allavena et al.,
1994) in our experimental model.
ADA prevented rolling velocity and rolling ﬂux triggered by IL-
23 in PBMC, but not in PMN. This was not expected, as there is no
previous functional evidence of such an action. This could have
been the result of the blockade of the TNF-α produced, in con-
junction with other cytokines (interferon-γ, interleukin-17, inter-
leukin-22…), by PBMC (Lowes et al., 2013) – but not by PMN
(Allavena et al., 1994; Suzuki et al., 2014) – in response to IL-12 and
IL-23 stimulation.5. Conclusions
In summary, our results demonstrate that clinically relevant
concentrations of three distinct and widely used anti-TNF-α drugs
inhibit the leukocyte recruitment induced by a wide variety of
stimuli that act on both the endothelium and leukocytes. UST
exhibits a more discreet proﬁle, blocking the actions of IL-23 and
IL-12 on leukocyte activation without modifying those arising
from endothelial stimuli activation. These ﬁndings endorse the
idea that treatment with currently prescribed biological anti-in-
ﬂammatory drugs can have a positive impact on CVD risk by re-
ducing the vascular systemic inﬂammation associated with PS and
C. Ríos-Navarro et al. / European Journal of Pharmacology 765 (2015) 355–365364RA. However, the degree of such effects varies considerably; in
light of our in vitro results obtained in human cells, the wider
proﬁle of actions of anti-TNF-α – owing to the ubiquity of the
mediator in the inﬂammatory cascade – seems to promise a more
potent, and thus more clinically relevant effect. Importantly, this
potential CV effect is in addition to these drugs’ ability to coun-
teract the inﬂammatory conditions that characterize the derma-
tologic and rheumatic diseases for whose treatment they were
designed, and obviously requires clinical corroboration.Conﬂict of interest
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